These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24458521)

  • 1. Fibronectin is a serum biomarker for Duchenne muscular dystrophy.
    Cynthia Martin F; Hiller M; Spitali P; Oonk S; Dalebout H; Palmblad M; Chaouch A; Guglieri M; Straub V; Lochmüller H; Niks EH; Verschuuren JJ; Aartsma-Rus A; Deelder AM; van der Burgt YE; 't Hoen PA
    Proteomics Clin Appl; 2014 Apr; 8(3-4):269-78. PubMed ID: 24458521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower Extremity Muscle Involvement in the Intermediate and Bethlem Myopathy Forms of COL6-Related Dystrophy and Duchenne Muscular Dystrophy: A Cross-Sectional Study.
    Batra A; Lott DJ; Willcocks R; Forbes SC; Triplett W; Dastgir J; Yun P; Reghan Foley A; Bönnemann CG; Vandenborne K; Walter GA
    J Neuromuscul Dis; 2020; 7(4):407-417. PubMed ID: 32538860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
    JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy.
    Rouillon J; Zocevic A; Leger T; Garcia C; Camadro JM; Udd B; Wong B; Servais L; Voit T; Svinartchouk F
    Neuromuscul Disord; 2014 Jul; 24(7):563-73. PubMed ID: 24813925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies.
    Spitali P; Hettne K; Tsonaka R; Charrout M; van den Bergen J; Koeks Z; Kan HE; Hooijmans MT; Roos A; Straub V; Muntoni F; Al-Khalili-Szigyarto C; Koel-Simmelink MJA; Teunissen CE; Lochmüller H; Niks EH; Aartsma-Rus A
    J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):715-726. PubMed ID: 29682908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients.
    Oonk S; Spitali P; Hiller M; Switzar L; Dalebout H; Calissano M; Lochmüller H; Aartsma-Rus A; 't Hoen PA; van der Burgt YE
    Proteomics Clin Appl; 2016 Mar; 10(3):290-9. PubMed ID: 26680509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy.
    Hathout Y; Brody E; Clemens PR; Cripe L; DeLisle RK; Furlong P; Gordish-Dressman H; Hache L; Henricson E; Hoffman EP; Kobayashi YM; Lorts A; Mah JK; McDonald C; Mehler B; Nelson S; Nikrad M; Singer B; Steele F; Sterling D; Sweeney HL; Williams S; Gold L
    Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7153-8. PubMed ID: 26039989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
    Hu J; Kong M; Ye Y; Hong S; Cheng L; Jiang L
    J Neurochem; 2014 Jun; 129(5):877-83. PubMed ID: 24460924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy.
    Matsuzaka Y; Kishi S; Aoki Y; Komaki H; Oya Y; Takeda S; Hashido K
    Environ Health Prev Med; 2014 Nov; 19(6):452-8. PubMed ID: 25150707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection.
    Anaya-Segura MA; García-Martínez FA; Montes-Almanza LA; Díaz BG; Avila-Ramírez G; Alvarez-Maya I; Coral-Vazquez RM; Mondragón-Terán P; Escobar-Cedillo RE; García-Calderón N; Vazquez-Cardenas NA; García S; López-Hernandez LB
    Molecules; 2015 Jun; 20(6):11154-72. PubMed ID: 26091074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.
    Boca SM; Nishida M; Harris M; Rao S; Cheema AK; Gill K; Seol H; Morgenroth LP; Henricson E; McDonald C; Mah JK; Clemens PR; Hoffman EP; Hathout Y; Madhavan S
    PLoS One; 2016; 11(4):e0153461. PubMed ID: 27082433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients.
    Capitanio D; Moriggi M; Torretta E; Barbacini P; De Palma S; Viganò A; Lochmüller H; Muntoni F; Ferlini A; Mora M; Gelfi C
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):547-563. PubMed ID: 31991054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digital PCR quantification of miR-30c and miR-181a as serum biomarkers for Duchenne muscular dystrophy.
    Llano-Diez M; Ortez CI; Gay JA; Álvarez-Cabado L; Jou C; Medina J; Nascimento A; Jimenez-Mallebrera C
    Neuromuscul Disord; 2017 Jan; 27(1):15-23. PubMed ID: 27979502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.
    Hoffman EP
    Acta Myol; 2020 Dec; 39(4):179-186. PubMed ID: 33458572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valley sign in Becker muscular dystrophy and outliers of Duchenne and Becker muscular dystrophy.
    Pradhan S
    Neurol India; 2004 Jun; 52(2):203-5. PubMed ID: 15269471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).
    Nadarajah VD; van Putten M; Chaouch A; Garrood P; Straub V; Lochmüller H; Ginjaar HB; Aartsma-Rus AM; van Ommen GJ; den Dunnen JT; 't Hoen PA
    Neuromuscul Disord; 2011 Aug; 21(8):569-78. PubMed ID: 21724396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.
    Gatheridge MA; Kwon JM; Mendell JM; Scheuerbrandt G; Moat SJ; Eyskens F; Rockman-Greenberg C; Drousiotou A; Griggs RC
    JAMA Neurol; 2016 Jan; 73(1):111-6. PubMed ID: 26594870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy.
    Zaharieva IT; Calissano M; Scoto M; Preston M; Cirak S; Feng L; Collins J; Kole R; Guglieri M; Straub V; Bushby K; Ferlini A; Morgan JE; Muntoni F
    PLoS One; 2013; 8(11):e80263. PubMed ID: 24282529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum creatinine level: a supplemental index to distinguish Duchenne muscular dystrophy from Becker muscular dystrophy.
    Zhang H; Zhu Y; Sun Y; Liang Y; Li Y; Zhang Y; Deng L; Wen X; Zhang C
    Dis Markers; 2015; 2015():141856. PubMed ID: 25852218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.